FGP
KRYS icon

Freestone Grove Partners’s Krystal Biotech KRYS Stock Holding History

Freestone Grove Partners’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$342K Sell
920
-2,002
-69% -$598K ﹤0.01% 730
2026
Q1 		$755K Buy
+2,922
New +$778K 0.01% 529
2025
Q4 		– Sell
-2,031
Closed -$359K – 834
2025
Q3 		$359K Buy
2,031
+136
+7% +$20.4K ﹤0.01% 587
2025
Q2 		$260K Buy
+1,895
New +$278K ﹤0.01% 604

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Freestone Grove Partners's KRYS Position: Q2 2026 in Review

Freestone Grove Partners reduced its Krystal Biotech (KRYS) stake by 69% in Q2 2026, selling an estimated $598K and leaving 920 shares worth $342K. The position accounts for ﹤0.01% of the portfolio, ranked #730.

Freestone Grove Partners first reported a position in KRYS in Q2 2025 and has held it in 4 quarters since. The position peaked at $755K in Q1 2026. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Freestone Grove Partners held 920 shares of Krystal Biotech worth $342K as of Q2 2026.
  • Freestone Grove Partners sold 2,002 Krystal Biotech shares in Q2 2026, an estimated $598K.
  • Krystal Biotech made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #730 holding.
  • Freestone Grove Partners first reported a position in Krystal Biotech in Q2 2025 and has held it in 4 quarters since.
  • Freestone Grove Partners's Krystal Biotech position peaked at $755K in Q1 2026.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.